Ibuprofen API Market Analysis

  • Report ID: 5471
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Ibuprofen API Market Analysis

Application (Headache, Arthritis)

The arthritis segment in the ibuprofen API market is projected to gather the largest share of about 60% during the forecast period. This could be owing to the growing prevalence of arthritis. Millions of people globally suffer from arthritis. Approximately 1 in 5 individuals in the US have a medically diagnosed case of arthritis. Extreme joint pain brought on by arthritis may render it difficult for patients to engage in daily activities. Their ability to work, engage in healthy physical activity, and maintain their mental health may all be impacted by this. Hence, the demand for ibuprofen active pharmaceutical ingredient (API) is growing. Rheumatoid arthritis and other inflammatory arthritis can be treated with higher dosages of ibuprofen, which are prescribed. Ibuprofen is equally effective as aspirin along with other nonsteroidal anti-inflammatory medications (NSAIDs) in treating rheumatoid arthritis. Ibuprofen contrasts positively to other NSAIDs and has a tolerability and safety profile that is superior to that of aspirin. 

End-User (CROs & CMOs, Pharmaceutical & Biopharmaceutical Companies)

The pharmaceutical & biopharmaceutical companies segment is expected to hold 60% share of the global ibuprofen API market during the forecast period. There has been a surge in the development of pharmaceutical & biopharmaceutical companies due to which the development of ibuprofen API is rising. Additionally, the investment made by the government is also high in this sector which is why the manufacturing of medications is carried out at an expanded ratio. Additionally, more prevalence is given to biopharmaceutical companies as a result of the combination of biopharmaceutical products' safety, efficacy, and ability to cure illnesses that were previously incurable. For instance, ibuprofen is a class IIa medication (low solubility, high permeability) in the Biopharmaceutics Classification System (BCS) that is used as an anti-inflammatory, analgesic, and antipyretic.

Our in-depth analysis of the global ibuprofen API market includes the following segments:

          Application

  • Headache
  • Arthritis

          End-User

  • CROs & CMOs
  • Pharmaceutical & Biopharmaceutical Companies
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5471
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of ibuprofen API is estimated at USD 727.09 million.

The ibuprofen API market size was over USD 715.08 million in 2024 and is expected to cross USD 936.89 million by the end of 2037, growing at more than 2.1% CAGR during the forecast period i.e., between 2025-2037. The market growth is propelled by growth in number of women menstruating, rise in need for growth in drug development, and surge in prevalence of musculoskeletal disorders in pediatrics.

Asia Pacific industry is set to account for largest revenue share 35% by 2037, owing to low manufacturing cost of manufacturing medicines in the region.

The major players in the market are Azelis, Lonza, BIOCAUSE Inc., IOL Chemicals and Pharmaceuticals Limited and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample